Dashboard
Manage Tickers

ARVN ARVINAS, INC.


$ 9.32 $ 0.05 (0.55 %)    

Friday, 24-Oct-2025 16:56:00 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 617.50 $ 6.52 (1.07 %)
DIA $ 472.45 $ 4.92 (1.05 %)
SPY $ 677.25 $ 5.49 (0.82 %)
TLT $ 91.47 $ 0.04 (0.04 %)
GLD $ 378.59 $ -1.27 (-0.34 %)
$ na
$ 9.25
$ 9.22 x 10
$ 9.80 x 280
$ 9.09 - $ 9.55
$ 5.90 - $ 29.61
3,459,584
na
676.18M
$ 1.39
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

arvinas-announces-preclinical-data-for-arv-806-showing-robust-differentiated-activity-in-models-of-kras-g12d-mutated-cancer-at-2025-aacr-nci-eortc-international-conference
Arvinas Announces Preclinical Data For ARV...
10/24/2025 20:02:42

– In vivo, ARV-806 demonstrated robust and durable KRAS G12D degradation, leading to significant tumor growth inhibition in mod...

arvinas-to-present-preclinical-data-for-arv-806-at-2025-at-aacr-nci-eortc-international-conference-in-boston
Arvinas To Present Preclinical Data For AR...
10/22/2025 20:03:04

arvinas-reports-vepdegestrant-maintained-quality-of-life-and-delayed-symptom-worsening-in-esr1-mutated-erher2--advanced-breast-cancer-patients
Arvinas Reports Vepdegestrant Maintained Q...
10/20/2025 08:36:04

– Data demonstrated that vepdegestrant maintained patients' quality of life for statistically significantly longer and dela...

forecasting-the-future-7-analyst-projections-for-arvinas
Forecasting The Future: 7 Analyst Projecti...
10/15/2025 22:01:44

this-ge-vernova-analyst-turns-bearish-here-are-top-5-downgrades-for-wednesday
This GE Vernova Analyst Turns Bearish; Her...
10/15/2025 13:49:56

karooooo-posts-downbeat-earnings-joins-asp-isotopes-and-other-big-stocks-moving-lower-in-wednesdays-pre-market-session
Karooooo Posts Downbeat Earnings, Joins AS...
10/15/2025 12:01:14

goldman-sachs-downgrades-arvinas-to-sell-lowers-price-target-to-6
Goldman Sachs Downgrades Arvinas to Sell, ...
10/15/2025 11:24:51

Goldman Sachs analyst Paul Choi downgrades Arvinas (NASDAQ:ARVN) from Neutral to Sell and lowers the price target from $8 to...

Core News & Articles
Arvinas And Pfizer To Highlight New Vepdeg...
10/13/2025 11:08:29

Presentation to include new patient-reported outcomes (PRO) data from the Phase 3 VERITAC-2 clinical trial 

reported-sunday-arvinas-unveils-late-breaking-phase-1-data-for-arv-102-showing-90-lrrk2-reduction-and-modulation-of-neuroinflammatory-pathways
Reported Sunday, Arvinas Unveils Late-Brea...
10/06/2025 06:29:32

arvinas-to-present-arv-102-data-at-2025-international-congress-of-parkinsons-disease-and-movement-disorders-oct-7-and-8
Arvinas To Present ARV-102 Data At 2025 In...
10/01/2025 11:03:59

btig-maintains-buy-on-arvinas-lowers-price-target-to-10
BTIG Maintains Buy on Arvinas, Lowers Pric...
09/18/2025 14:08:11

BTIG analyst Jeet Mukherjee maintains Arvinas (NASDAQ:ARVN) with a Buy and lowers the price target from $16 to $10.

stephens--co-maintains-overweight-on-arvinas-lowers-price-target-to-14
Stephens & Co. Maintains Overweight on Arv...
09/18/2025 12:03:47

Stephens & Co. analyst Sudan Loganathan maintains Arvinas (NASDAQ:ARVN) with a Overweight and lowers the price target fr...

arvinas-to-reduce-workforce-by-15-most-significant-reductions-being-roles-related-to-vepdegestrant-commercialization-expects-45m-costs-for-workforce-reduction
Arvinas To Reduce Workforce By 15%; Most S...
09/17/2025 20:53:03

arvinas-says-additional-cost-optimization-measures-expected-to-realize-total-annual-savings-of-more-than-100m-compared-to-fy24-board-authorizes-100m-stock-repurchase
Arvinas Says Additional Cost Optimization ...
09/17/2025 20:33:10

Core News & Articles
Arvinas Provides Update On Pfizer Collabor...
09/17/2025 20:32:31

what-4-analyst-ratings-have-to-say-about-arvinas
What 4 Analyst Ratings Have To Say About A...
09/17/2025 12:00:52

Core News & Articles
Arvinas And Pfizer Announce FDA Accepts Ne...
08/08/2025 20:06:48

– Filing based on pivotal Phase 3 VERITAC-2 clinical trial demonstrating statistically significant and clinically meaningful im...

hc-wainwright--co-maintains-buy-on-arvinas-lowers-price-target-to-18
HC Wainwright & Co. Maintains Buy on Arvin...
08/07/2025 15:49:27

HC Wainwright & Co. analyst Andrew S. Fein maintains Arvinas (NASDAQ:ARVN) with a Buy and lowers the price target from $...

wells-fargo-maintains-overweight-on-arvinas-lowers-price-target-to-16
Wells Fargo Maintains Overweight on Arvina...
08/07/2025 14:30:56

Wells Fargo analyst Derek Archila maintains Arvinas (NASDAQ:ARVN) with a Overweight and lowers the price target from $19 to ...

guggenheim-maintains-buy-on-arvinas-lowers-price-target-to-15
Guggenheim Maintains Buy on Arvinas, Lower...
08/07/2025 14:14:07

Guggenheim analyst Michael Schmidt maintains Arvinas (NASDAQ:ARVN) with a Buy and lowers the price target from $16 to $15.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION